Suchergebnisse - "rucaparib"

PubPharm (7)

1

Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations

enthalten in: The Lancet. Oncology | 2022

von Ganguly, S. | Gogia, A.

CommentOn: Lancet Oncol. 2022 Apr;23(4):465-478. - PMID 35298906

2

Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations - Authors' reply

enthalten in: The Lancet. Oncology | 2022

von Kristeleit, R. | Oza, A.

CommentOn: Lancet Oncol. 2022 Apr;23(4):465-478. - PMID 35298906

3

Rucaparib for BRCA1/2-mutated pretreated ovarian cancer : reflections from the ARIEL4 trial

enthalten in: The Lancet. Oncology | 2022

von O'Donnell, D.

CommentOn: Lancet Oncol. 2022 Apr;23(4):465-478. - PMID 35298906

4

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4) : an international, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2022

von Kristeleit, R. | Lisyanskaya, A. | Fedenko, A. | +22

CommentIn: Lancet Oncol. 2022 Apr;23(4):440-441. - PMID 35298905

5

Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3) : post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2020

von Ledermann, J. | Oza, A. | Lorusso, D. | +21

CommentIn: Lancet Oncol. 2020 May;21(5):616-617. - PMID 32359486

6

Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer : updates from the ARIEL3 trial

enthalten in: The Lancet. Oncology | 2020

von Tomao, F. | Vici, P. | Tomao, S.

CommentOn: Lancet Oncol. 2020 May;21(5):710-722. - PMID 32359490

7

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1) : an international, multicentre, open-label, phase 2 trial

enthalten in: The Lancet. Oncology | 2017

von Swisher, E. | Lin, K. | Oza, A. | +28

CommentIn: Lancet Oncol. 2017 Jan;18(1):8-9. - PMID 27908593

1
[1]